GO:0017060 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0017060 describes the enzymatic activity that transfers L-fucose from GDP-L-fucose onto the 4-position of N-acetylglucosamine within a 3-galactosyl-N-acetylglucosaminide acceptor, creating the Lewis A (Lea) blood group epitope.
• This alpha-1,4-fucosyltransferase activity is distinct from alpha-1,3-fucosyltransferase activity, although both can be catalyzed by the same Lewis enzyme (FUT3) depending on acceptor structure.
• The enzyme is a type II Golgi membrane glycosyltransferase that uses GDP-L-fucose as the donor substrate and requires a terminal beta-galactose on the acceptor for optimal activity.
• Alpha-1,4-fucosyltransferase activity is detectable in human milk, serum, saliva, and various adult tissues, with differential expression during embryonic development.
• Altered fucosylation, including alpha-1,4-fucosylation, influences tumor marker levels such as CA19-9 and DUPAN-2, which are used in pancreatic cancer diagnostics.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable causal interrogation of fucosyltransferase genes and their roles in glycosylation, immunity, and cancer.
Description
GO:0017060, 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity, is a molecular function that catalyzes the transfer of L-fucose from GDP-L-fucose to the 4-position of N-acetylglucosamine in a beta-D-galactosyl-(1,3)-N-acetyl-D-glucosaminyl-R acceptor, yielding GDP and a beta-D-galactosyl-(1,3)-[alpha-L-fucosyl-(1,4)]-N-acetyl-D-glucosaminyl-R product. This reaction generates the Lewis A (Lea) blood group antigen and is a key step in the biosynthesis of fucosylated glycans that mediate cell-cell recognition, host-microbe interactions, and immune regulation. The enzyme responsible is often referred to as alpha-1,4-fucosyltransferase or Lewis FT, and it can also exhibit alpha-1,3-fucosyltransferase activity depending on the acceptor substrate. Researchers study GO:0017060 because fucosylated glycans are involved in diverse physiological and pathological processes, including blood group antigen presentation, Helicobacter pylori adhesion, and cancer progression. The activity is found in human milk, serum, saliva, and multiple tissues, and its expression varies during embryonic development and in adult organs. In cancer, altered fucosylation can affect the diagnostic performance of tumor markers such as CA19-9 and DUPAN-2, making this activity relevant to clinical oncology. Understanding the enzymatic properties, substrate specificity, and regulation of GO:0017060 is essential for glycobiology, transfusion medicine, and cancer biomarker research. This article integrates authoritative QuickGO annotation data with verified PubMed literature to provide a research-grade overview of the mechanism, genes, disease links, and experimental models associated with this fucosyltransferase activity.
3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity At A Glance
| GO ID | GO:0017060 |
|---|---|
| GO term | 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity |
| Ontology | molecular_function |
| Synonym | alpha-(1,4)-L-fucosyltransferase activity; blood group Lewis alpha-4-fucosyltransferase activity; FucT-II activity; Lewis FT activity |
| Major function | Transfer of L-fucose from GDP-L-fucose to the 4-position of N-acetylglucosamine in a 3-galactosyl-N-acetylglucosaminide acceptor, forming Lewis A antigen |
| Substrate | GDP-L-fucose (donor); beta-D-galactosyl-(1,3)-N-acetyl-D-glucosaminyl-R (acceptor) |
| Product | GDP; beta-D-galactosyl-(1,3)-[alpha-L-fucosyl-(1,4)]-N-acetyl-D-glucosaminyl-R |
| Cellular location | Golgi apparatus membrane (type II membrane protein) |
| Tissue distribution | Human milk, serum, saliva, and various adult tissues; differential expression during embryonic development |
What Is GO:0017060?
GO:0017060 is defined as the catalysis of the reaction: GDP-L-fucose + beta-D-galactosyl-(1,3)-N-acetyl-D-glucosaminyl-R = GDP + beta-D-galactosyl-(1,3)-[alpha-L-fucosyl-(1,4)]-N-acetyl-D-glucosaminyl-R. In simpler terms, it is an enzyme activity that attaches a fucose sugar to a specific position on a glycan chain, forming a Lewis A structure. This activity is also known as alpha-1,4-fucosyltransferase, blood group Lewis alpha-4-fucosyltransferase, and FucT-II, among other synonyms.
Why Is 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity Important in Cell Biology?
GO:0017060 is important because it governs the biosynthesis of Lewis A and related fucosylated glycans that function in blood group antigen display, host-pathogen interactions, and cancer biomarker expression. The activity is critical for generating ligands recognized by lectins and antibodies, and its dysregulation can alter cell surface glycosylation, impacting immune recognition and tumor progression. Studying this activity helps researchers understand glycosylation pathways, develop diagnostic tools, and design therapeutic strategies targeting fucosylation.
• Generates the Lewis A blood group antigen, which is relevant to transfusion medicine and organ transplantation.
• Modulates host-microbe interactions, including Helicobacter pylori binding to gastric glycosphingolipids.
• Influences cancer biomarker levels such as CA19-9 and DUPAN-2, which are used in pancreatic cancer diagnosis.
• Contributes to the synthesis of fucosylated glycans involved in cell adhesion and signaling.
• Exhibits differential expression during embryonic development and in adult tissues, suggesting roles in development and tissue homeostasis.
• Can be targeted by CRISPR-based gene editing to study loss-of-function phenotypes in glycosylation.
• Provides a model for understanding enzyme substrate specificity within the fucosyltransferase family.
• Has clinical relevance in serum and saliva diagnostics due to its presence in body fluids.
• Enables structural and biochemical studies of alpha-1,4-fucosyltransferases, as exemplified by the mango enzyme crystal structure.
• Serves as a potential therapeutic target in diseases where fucosylation is aberrant.
Molecular Mechanism of 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity
Substrate Recognition and Binding
In simple terms: The enzyme grabs a fucose donor and a sugar chain acceptor, positioning them for transfer.
The enzyme binds GDP-L-fucose as the donor substrate and a beta-D-galactosyl-(1,3)-N-acetyl-D-glucosaminyl-R acceptor. The acceptor typically requires a terminal beta-galactose linked to N-acetylglucosamine, as demonstrated by studies on alpha-1,4-fucosyltransferase from human milk and serum. Synthetic oligosaccharide acceptors have been used to define specificity patterns, showing that the enzyme recognizes the 3-galactosyl-N-acetylglucosaminide motif.
Catalytic Transfer of Fucose
In simple terms: The enzyme snips off fucose from GDP and attaches it to the sugar chain at the 4-position.
The catalytic mechanism involves the transfer of L-fucose from GDP-L-fucose to the 4-position of N-acetylglucosamine, forming an alpha-1,4-linkage. This reaction releases GDP and produces the Lewis A epitope. The enzyme can also catalyze alpha-1,3-fucosylation depending on the acceptor, but GO:0017060 specifically refers to the alpha-1,4 activity. Enzymatic properties of a melanoma-derived alpha-3-fucosyltransferase highlight the importance of acceptor structure in determining linkage specificity.
Structural Determinants of Specificity
In simple terms: The shape of the enzyme's active site decides which sugar linkage it makes.
Crystal structure analysis of mango alpha-1,3/alpha-1,4-fucosyltransferase has elucidated unique elements that regulate Lewis A-dominant oligosaccharide assembly, providing insights into how the enzyme accommodates different acceptors. These structural features help explain the dual specificity observed in some fucosyltransferases, including the human Lewis enzyme.
Cofactors and Reaction Conditions
In simple terms: The enzyme needs GDP-fucose and specific pH and ion conditions to work efficiently.
The reaction requires GDP-L-fucose as the fucose donor; no other cofactors are known to be essential. Enzymatic studies on alpha-1,4-fucosyltransferase from human serum and saliva have characterized optimal pH and kinetic parameters. The enzyme is membrane-bound and functions in the Golgi lumen, where the necessary substrates are available.
Regulation of Enzyme Activity
In simple terms: The enzyme's activity can be turned up or down by gene expression and cellular conditions.
Expression of alpha-1,4-fucosyltransferase activity varies across tissues and developmental stages, as shown by differential expression during human embryonic development and in adult tissues. The activity is also released into culture medium by A431 epidermoid carcinoma cells, suggesting soluble forms may exist. Regulation likely occurs at the transcriptional level and through post-translational modifications, though specific mechanisms require further study.
Key Genes Involved in GO:0017060 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity
The following genes and proteins are directly or indirectly associated with GO:0017060 activity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FUT3 | Encodes the Lewis enzyme with alpha-1,3/4-fucosyltransferase activity; synthesizes Lewis A and Lewis B antigens | Key target for studying blood group antigens and cancer-associated fucosylation |
| FUT4 | Alpha-1,3-fucosyltransferase; may contribute to related fucosylation but distinct from GO:0017060 | Model for comparing alpha-1,3 versus alpha-1,4 specificity |
| FUT5 | Alpha-1,3-fucosyltransferase; not directly linked to alpha-1,4 activity | Used in specificity studies of fucosyltransferase family |
| FUT6 | Alpha-1,3-fucosyltransferase; involved in Lewis X synthesis | Contrasts with alpha-1,4 activity in glycan profiling |
| FUT7 | Alpha-1,3-fucosyltransferase; roles in selectin ligand synthesis | Reference for fucosyltransferase diversity |
| FUT9 | Alpha-1,3-fucosyltransferase; not alpha-1,4 | Comparative studies of enzyme specificity |
| GDP-fucose transporter (SLC35C1) | Transports GDP-fucose into Golgi for fucosylation reactions | Required for substrate supply; knockout affects all fucosylation |
| B3GALT5 | Beta-1,3-galactosyltransferase; generates the 3-galactosyl-N-acetylglucosaminide acceptor | Upstream enzyme providing substrate for GO:0017060 |
| B3GNT3 | Beta-1,3-N-acetylglucosaminyltransferase; involved in poly-N-acetyllactosamine synthesis | May influence acceptor availability |
| GCNT1 | Beta-1,6-N-acetylglucosaminyltransferase; modifies core structures | Alters glycan branching and acceptor presentation |
| ST3GAL4 | Sialyltransferase; competes with fucosylation for acceptor sites | Affects CA19-9 and DUPAN-2 levels |
| ST6GAL1 | Sialyltransferase; modifies terminal glycans | Impacts tumor marker glycosylation |
| B4GALT1 | Beta-1,4-galactosyltransferase; extends glycan chains | Provides substrates for fucosylation |
| MGAT1 | Alpha-1,3-mannosyl-glycoprotein beta-1,2-N-acetylglucosaminyltransferase; N-glycan processing | Indirectly affects complex glycan synthesis |
| FUT2 | Alpha-1,2-fucosyltransferase; synthesizes Lewis B and H antigens | Interacts with FUT3 in blood group synthesis |
| FUT1 | Alpha-1,2-fucosyltransferase; H antigen synthesis | Related to Lewis antigen pathways |
| GALNT1 | Polypeptide N-acetylgalactosaminyltransferase; O-glycosylation | May influence mucin-type O-glycan acceptors |
| B3GAT1 | Beta-1,3-glucuronyltransferase; not directly linked | General glycosylation reference |
How Is 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity Regulated?
The activity of GO:0017060 is regulated primarily at the level of gene expression, with differential expression observed during human embryonic development and across adult tissues. The enzyme is a type II Golgi membrane protein, and its localization ensures access to GDP-L-fucose and acceptor substrates in the Golgi lumen. Soluble forms of the enzyme can be released into culture medium, as shown for A431 epidermoid carcinoma cells, suggesting potential extracellular regulation. Additionally, substrate availability, including GDP-fucose transport and acceptor synthesis by other glycosyltransferases, indirectly modulates the reaction. No specific allosteric or post-translational regulators have been definitively established in the verified literature.
3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FUT3 | Lewis blood group phenotype; cancer-associated fucosylation | Knockout in cancer cell lines; point mutation to alter specificity |
| FUT3 | Helicobacter pylori adhesion | Transgenic mouse expressing human FUT3 in stomach |
| FUT3 | Pancreatic cancer biomarker modulation | CRISPR knock-in of variants in pancreatic cell lines |
| FUT3 | Altered serum and saliva fucosylation | Overexpression in HEK293 cells for enzyme purification |
| B3GALT5 | Substrate supply for Lewis A synthesis | Knockout to reduce acceptor availability |
Cancer and Tumor Markers
Altered alpha-1,4-fucosyltransferase activity contributes to the synthesis of tumor-associated carbohydrate antigens. In pancreatic cancer, variants in tumor marker genes improve the diagnostic accuracy of DUPAN-2 and CA19-9, which are influenced by fucosylation pathways. The expression of alpha-1,3/4-fucosyltransferase in cancer cell lines, such as A431 epidermoid carcinoma, indicates a role in tumor glycosylation. These findings suggest that GO:0017060 activity may be a biomarker or therapeutic target in cancers with aberrant fucosylation.
Helicobacter pylori Infection
Expression of human alpha-1,3/4-fucosyltransferase in FVB/N mouse stomach creates a novel Lewis B-like Helicobacter pylori-binding glycosphingolipid, demonstrating that this enzyme activity can generate ligands for bacterial adhesion. This links GO:0017060 to host-pathogen interactions and gastric disease.
Blood Group and Transfusion Medicine
The Lewis A antigen produced by GO:0017060 is a blood group substance. Co-purification of the Lewis blood group alpha-1,4-fucosyltransferase from human milk highlights its role in blood group antigen biosynthesis. Understanding this activity is relevant for transfusion compatibility and organ transplantation.
From 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of FUT3 abolish alpha-1,4-fucosyltransferase activity? | CRISPR knockout of FUT3 in human cell lines (e.g., A431, HEK293) |
| How do point mutations in the catalytic domain affect substrate specificity? | CRISPR point mutation knock-in of FUT3 variants |
| Can a tagged FUT3 be used to track Golgi localization? | Knock-in of fluorescent or epitope tag at the endogenous FUT3 locus |
| Does overexpression of FUT3 increase Lewis A antigen levels? | Stable overexpression of FUT3 in mammalian cells |
| What is the role of FUT3 in Helicobacter pylori binding? | Transgenic mouse expressing human FUT3 in gastric epithelium |
| Can CRISPR library screening identify modifiers of fucosylation? | Genome-wide CRISPR knockout library in glycoengineered cells |
How to Study the 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive fucosyltransferase assay | Enzyme activity using GDP-[14C]-fucose | Kinetic characterization of FUT3 variants |
| Mass spectrometry | Glycan composition and linkage | Detection of Lewis A in biological samples |
| Lectin blotting | Presence of specific glycan epitopes | Screening for fucosylation changes |
| CRISPR knockout screening | Gene requirements for fucosylation | Identification of pathway modifiers |
| X-ray crystallography | Three-dimensional enzyme structure | Understanding substrate specificity |
| Flow cytometry | Cell surface glycan expression | Analysis of Lewis antigens on cells |
| qRT-PCR | mRNA expression of FUT genes | Tissue-specific expression profiling |
| Immunohistochemistry | Tissue distribution of Lewis antigens | Cancer biomarker studies |
Enzymatic Assays
Alpha-1,4-fucosyltransferase activity can be measured using synthetic oligosaccharide acceptors and GDP-[14C]-fucose, followed by product separation and quantification. These assays define substrate specificity and kinetic parameters.
Glycan Profiling
Mass spectrometry and lectin blotting can detect Lewis A and related fucosylated structures on glycoproteins and glycolipids, providing readouts for GO:0017060 activity in cells and tissues.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that regulate fucosylation, including transporters and glycosyltransferases that supply substrates for GO:0017060.
Structural Biology
X-ray crystallography of fucosyltransferases, such as the mango alpha-1,3/alpha-1,4-fucosyltransferase, reveals active site architecture and determinants of acceptor specificity.
How CRISPR Can Be Used to Study GO:0017060 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity
Knockout
CRISPR knockout of FUT3 or other fucosyltransferase genes can abolish alpha-1,4-fucosyltransferase activity, enabling studies of downstream effects on glycan structure, cell adhesion, and tumor marker expression. Knockout models are essential for establishing causality in glycosylation pathways.
Point Mutation
Introducing point mutations in the catalytic domain of FUT3 via CRISPR can dissect residues critical for donor and acceptor specificity, distinguishing alpha-1,4 from alpha-1,3 activity. Such models help map structure-function relationships.
Knock-in
Knock-in of epitope tags or fluorescent reporters at the endogenous FUT3 locus allows real-time tracking of enzyme localization and dynamics in the Golgi. Knock-in of disease-associated variants can model altered fucosylation in cancer.
Overexpression
CRISPR activation or stable overexpression of FUT3 increases alpha-1,4-fucosyltransferase activity, facilitating biochemical purification and glycan analysis. Overexpression models are useful for producing Lewis A-enriched glycans for functional studies.
How EDITGENE Supports 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity Research
Researchers studying 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in glycan biosynthesis, disease progression, or biomarker expression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity research.
Frequently Asked Questions About 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity
What is GO:0017060?
GO:0017060 is the Gene Ontology molecular function term for 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity, which catalyzes the transfer of fucose from GDP-L-fucose to the 4-position of N-acetylglucosamine in a specific glycan acceptor, forming Lewis A antigen.
What genes are involved in 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity?
The primary gene is FUT3, which encodes the Lewis enzyme with alpha-1,3/4-fucosyltransferase activity. Other genes such as B3GALT5 and SLC35C1 provide substrates or transport GDP-fucose for the reaction.
What is the difference between alpha-1,3 and alpha-1,4-fucosyltransferase activity?
Alpha-1,3-fucosyltransferase adds fucose to the 3-position of N-acetylglucosamine, while alpha-1,4-fucosyltransferase (GO:0017060) adds fucose to the 4-position. Some enzymes, like FUT3, can catalyze both reactions depending on the acceptor substrate.
Which diseases are associated with alpha-1,4-fucosyltransferase activity?
Altered activity is linked to cancer biomarker expression (e.g., CA19-9, DUPAN-2 in pancreatic cancer) and Helicobacter pylori adhesion in the stomach.
How can I measure alpha-1,4-fucosyltransferase activity in the lab?
Common methods include radioactive enzymatic assays using GDP-[14C]-fucose and synthetic acceptors, mass spectrometry for glycan profiling, and lectin blotting for Lewis A detection.
What cell models are available for studying GO:0017060?
CRISPR knockout, point mutation, knock-in, and overexpression cell models can be generated in cell lines such as A431, HEK293, or cancer cell lines to study fucosylation.
Is alpha-1,4-fucosyltransferase activity present in human milk?
Yes, the Lewis blood group alpha-1,4-fucosyltransferase has been co-purified from human milk, where it contributes to oligosaccharide fucosylation.
Can CRISPR be used to study fucosyltransferase genes?
Yes, CRISPR-Cas9 can create knockout, point mutation, knock-in, and overexpression models to dissect the function of fucosyltransferases and their role in glycosylation.
What is the substrate for GO:0017060?
The substrates are GDP-L-fucose (donor) and beta-D-galactosyl-(1,3)-N-acetyl-D-glucosaminyl-R (acceptor).
Where is the enzyme located in the cell?
The enzyme is a type II Golgi membrane protein, functioning in the Golgi apparatus lumen.
Conclusion
GO:0017060, 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase activity, is a key enzymatic function in the biosynthesis of Lewis A and related fucosylated glycans. Its roles in blood group antigen presentation, host-pathogen interactions, and cancer biomarker expression make it a significant target for glycobiology and clinical research. Understanding its mechanism, regulation, and disease associations provides a foundation for developing diagnostic and therapeutic strategies. CRISPR-based gene editing offers powerful tools to interrogate the genes responsible for this activity, enabling precise knockout, point mutation, knock-in, and overexpression models. EDITGENE supports researchers in generating these models to advance the study of fucosylation in health and disease.
References
- 1. Prieels JP et al.. 1983. Enzymic properties of an N-acetylglucosaminide 3-alpha-L-fucosyltransferase of a wheat-germ agglutinin-resistant melanoma clone.. Eur J Biochem 130(2):347-51 PMID: 6687456
- 2. Prieels JP et al.. 1981. Co-purification of the Lewis blood group N-acetylglucosaminide alpha 1 goes to 4 fucosyltransferase and an N-acetylglucosaminide alpha 1 goes to 3 fucosyltransferase from human milk.. J Biol Chem 256(20):10456-63 PMID: 7287719
- 3. Johnson PH et al.. 1993. Purification and properties of the alpha-3/4-L-fucosyltransferase released into the culture medium during the growth of the human A431 epidermoid carcinoma cell line.. Glycoconj J 10(2):152-64 PMID: 8400824
- 4. Ando Y et al.. 2024. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer.. J Clin Oncol 42(18):2196-2206 PMID: 38457748
- 5. Okada T et al.. 2024. Crystal structure of mango α1,3/α1,4-fucosyltransferase elucidates unique elements that regulate Lewis A-dominant oligosaccharide assembly.. Glycobiology 34(5) PMID: 38376259
- 6. DeBose-Boyd RA et al.. 1996. alpha1,4-Fucosyltransferase activity in human serum and saliva.. Arch Biochem Biophys 335(1):109-17 PMID: 8914840
- 7. Fagerberg D et al.. 2009. Novel Leb-like Helicobacter pylori-binding glycosphingolipid created by the expression of human alpha-1,3/4-fucosyltransferase in FVB/N mouse stomach.. Glycobiology 19(2):182-91 PMID: 18997175
- 8. Mollicone R et al.. 1992. Five specificity patterns of (1----3)-alpha-L-fucosyltransferase activity defined by use of synthetic oligosaccharide acceptors. Differential expression of the enzymes during human embryonic development and in adult tissues.. Carbohydr Res 228(1):265-76 PMID: 1366057
